Complement Components in Peripheral Blood from Adult Patients with IDH Wild-Type Glioblastoma.

Background: The complement system seems to influence cancer pathophysiology. The primary aim of this study was to explore complement components associated with the classical pathway (CP) of the complement system in peripheral blood from patients with IDH-wild-type (IDH-wt) glioblastoma.

Methods: Patients undergoing primary surgery due to glioblastoma in the years 2019-2021 were prospectively included in the present study.

Combined anti-C1-INH and radiotherapy against glioblastoma.

Background: A more effective immune response against glioblastoma is needed in order to achieve better tumor control. Radiotherapy can induce anti-tumor mediated immune reactions, in addition to its dose response effects. The complement system can function as a bridge between innate and adaptive immune responses.

What is the role of CRP in glioblastoma?

Background: Glioblastoma is the most common primary malignant brain tumor in adults. Previous studies have suggested that CRP (C-reactive protein) could serve as a biomarker candidate as well as a prognostic factor in glioblastoma patients, and we here further investigate its potential role.

Materials And Methods: Publicly available datasets were used to compare gene expression between brain samples from glioblastoma patients and non-tumor tissue.

Upregulation of C1-inhibitor in pancreatic cancer.

Purpose: The complement system has recently sparked more interest in cancer research. The classical pathway is initiated by activation of the C1 complex, which irreversibly can be bound to and inhibited by C1-INH. We have previously shown that C1-INH is upregulated in human glioblastoma (astrocytoma grade IV) on both gene and protein level.

Anti-C1-inactivator treatment of glioblastoma.

Purpose: Glioblastoma multiforme (GBM) or astrocytoma grade IV is the most common type of primary brain tumor in adults. In the present study, we investigate the role of the complement system in the glioblastoma situation in an experimental model, since we have previously been able to show a blockade of this system in the glioblastoma setting.

Technique And Results: A GFP-positive glioblastoma cell line was used to induce glioblastomas subcutaneously in rats (n=42).